Vland Biotech: The company and its subsidiaries jointly applied for the registration certificate of the new veterinary drug for Mianping ointment, which has been approved

Vland Biotech announced that the company and its wholly-owned subsidiaries, Qingdao Vland Zhi Chong Biotechnology Co., Ltd. and Qingdao Kangdi'en Animal Pharmaceutical Co., Ltd., along with other units, jointly applied for "Mirtazapine Ointment" to be classified as a new type of veterinary drug (Category V), and recently received the "New Veterinary Drug Registration Certificate." This product is primarily used to control weight loss in cats and was jointly developed by the company and its wholly-owned subsidiaries in collaboration with multiple units, with a total R&D investment of 1.8622 million yuan. The acquisition of the new veterinary drug certificate is expected to bring new performance growth points to the company's business